Heron Therapeutics, Inc. /De/ financial data

Symbol
HRTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
4242 Campus Point Court, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
AP PHARMA INC /DE/ (to 1/7/2014), ADVANCED POLYMER SYSTEMS INC /DE/ (to 4/6/2001)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 237 % +4.3%
Quick Ratio 54 % -8.66%
Debt-to-equity -704 % +52.8%
Return On Equity 76.8 % -89.6%
Return On Assets -12.7 % +76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 152M shares +1.35%
Common Stock, Shares, Outstanding 150M shares +26.1%
Entity Public Float 120M USD -58.1%
Common Stock, Value, Issued 1.52M USD +7.51%
Weighted Average Number of Shares Outstanding, Basic 153M shares +5.41%
Weighted Average Number of Shares Outstanding, Diluted 153M shares +5.41%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 38.1M USD -10.2%
Selling and Marketing Expense 48.4M USD -33.8%
General and Administrative Expense 38.9M USD -35.4%
Costs and Expenses 125M USD -15.4%
Operating Income (Loss) -25.9M USD +78.5%
Net Income (Loss) Attributable to Parent -28M USD +76.6%
Earnings Per Share, Basic -0.12 USD/shares +86.7%
Earnings Per Share, Diluted -0.12 USD/shares +86.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.7M USD -26.2%
Cash, Cash Equivalents, and Short-term Investments 70.9M USD -8.4%
Accounts Receivable, after Allowance for Credit Loss, Current 67M USD +5.09%
Inventory, Net 46M USD +9.39%
Assets, Current 195M USD +0.62%
Property, Plant and Equipment, Net 15.4M USD -25.8%
Operating Lease, Right-of-Use Asset 3.47M USD -42.8%
Other Assets, Noncurrent 6.71M USD -19.8%
Assets 221M USD -3.68%
Accounts Payable, Current 10.2M USD +448%
Employee-related Liabilities, Current 8.53M USD -17.8%
Liabilities, Current 85.5M USD +7.27%
Operating Lease, Liability, Noncurrent 522K USD -85.2%
Other Liabilities, Noncurrent 241K USD 0%
Liabilities 261M USD +1.48%
Accumulated Other Comprehensive Income (Loss), Net of Tax 40K USD
Retained Earnings (Accumulated Deficit) -1.92B USD -1.48%
Stockholders' Equity Attributable to Parent -40M USD -44%
Liabilities and Equity 221M USD -3.68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.52M USD +61.8%
Net Cash Provided by (Used in) Financing Activities -208K USD +67.3%
Net Cash Provided by (Used in) Investing Activities 1.28M USD -96.5%
Common Stock, Shares Authorized 225M shares 0%
Common Stock, Shares, Issued 150M shares +26.1%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.23M USD -170%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.7M USD -26.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 649K USD
Deferred Tax Assets, Valuation Allowance 430M USD +1.65%
Deferred Tax Assets, Gross 431M USD +1.51%
Operating Lease, Liability 3.77M USD -42.3%
Payments to Acquire Property, Plant, and Equipment 224K USD -78.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.9M USD +76.7%
Lessee, Operating Lease, Liability, to be Paid 3.93M USD -44.3%
Property, Plant and Equipment, Gross 37.2M USD +2.03%
Operating Lease, Liability, Current 3.25M USD +8.34%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.14M USD +3.56%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.14M USD -0.48%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 160K USD -69.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.1M USD -27.5%
Deferred Tax Assets, Operating Loss Carryforwards 321M USD +2.28%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2.5M shares 0%
Unrecognized Tax Benefits 10.9M USD -2.96%
Additional Paid in Capital 1.88B USD +0.84%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 689K USD -4.04%
Share-based Payment Arrangement, Expense 15M USD -61.6%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%